[Pharmacotherapeutics for the new coronavirus pneumonia].
Identifieur interne : 002603 ( Ncbi/Merge ); précédent : 002602; suivant : 002604[Pharmacotherapeutics for the new coronavirus pneumonia].
Auteurs : B. Du [République populaire de Chine] ; H B Qiu [République populaire de Chine] ; X. Zhan [République populaire de Chine] ; Y S Wang [République populaire de Chine] ; H Y J. Kang [République populaire de Chine] ; X Y Li [République populaire de Chine] ; F. Wang [République populaire de Chine] ; B. Sun [République populaire de Chine] ; Z H Tong [République populaire de Chine]Source :
- Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [ 1001-0939 ] ; 2020.
Descripteurs français
- KwdFr :
- Adénosine (analogues et dérivés), Adénosine (usage thérapeutique), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Antibactériens (usage thérapeutique), Antiviraux, Association de médicaments, Chine, Humains, Infections à coronavirus (traitement médicamenteux), Inhibiteurs du cytochrome P-450 CYP3A (usage thérapeutique), Lopinavir (usage thérapeutique), Pneumopathie virale (traitement médicamenteux), Ribonucléotides (usage thérapeutique), Ritonavir (usage thérapeutique), Études rétrospectives.
- MESH :
- analogues et dérivés : Adénosine, Alanine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Adénosine, Alanine, Antibactériens, Inhibiteurs du cytochrome P-450 CYP3A, Lopinavir, Ribonucléotides, Ritonavir.
- Antiviraux, Association de médicaments, Chine, Humains, Études rétrospectives.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Adenosine (analogs & derivatives), Adenosine (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Anti-Bacterial Agents (therapeutic use), Antiviral Agents, China, Coronavirus Infections (drug therapy), Cytochrome P-450 CYP3A Inhibitors (therapeutic use), Drug Therapy, Combination, Humans, Lopinavir (therapeutic use), Pneumonia, Viral (drug therapy), Retrospective Studies, Ribonucleotides (therapeutic use), Ritonavir (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Adenosine, Alanine.
- chemical , therapeutic use : Adenosine, Alanine, Anti-Bacterial Agents, Cytochrome P-450 CYP3A Inhibitors, Lopinavir, Ribonucleotides, Ritonavir.
- chemical : Antiviral Agents.
- geographic : China.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Drug Therapy, Combination, Humans, Retrospective Studies.
Abstract
The new coronavirus pneumonia (NCP), also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and interferon-α is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on Middle East respiratory syndrome (MERS), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg·kg(-1)·d(-1), 3~5 d) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.
DOI: 10.3760/cma.j.issn.1001-0939.2020.03.005
PubMed: 32164081
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000168
- to stream PubMed, to step Curation: 000168
- to stream PubMed, to step Checkpoint: 000008
Links to Exploration step
pubmed:32164081Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Pharmacotherapeutics for the new coronavirus pneumonia].</title>
<author><name sortKey="Du, B" sort="Du, B" uniqKey="Du B" first="B" last="Du">B. Du</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Qiu, H B" sort="Qiu, H B" uniqKey="Qiu H" first="H B" last="Qiu">H B Qiu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009</wicri:regionArea>
<wicri:noRegion>Nanjing 210009</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhan, X" sort="Zhan, X" uniqKey="Zhan X" first="X" last="Zhan">X. Zhan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Y S" sort="Wang, Y S" uniqKey="Wang Y" first="Y S" last="Wang">Y S Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kang, H Y J" sort="Kang, H Y J" uniqKey="Kang H" first="H Y J" last="Kang">H Y J. Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, X Y" sort="Li, X Y" uniqKey="Li X" first="X Y" last="Li">X Y Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, F" sort="Wang, F" uniqKey="Wang F" first="F" last="Wang">F. Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sun, B" sort="Sun, B" uniqKey="Sun B" first="B" last="Sun">B. Sun</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tong, Z H" sort="Tong, Z H" uniqKey="Tong Z" first="Z H" last="Tong">Z H Tong</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32164081</idno>
<idno type="pmid">32164081</idno>
<idno type="doi">10.3760/cma.j.issn.1001-0939.2020.03.005</idno>
<idno type="wicri:Area/PubMed/Corpus">000168</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000168</idno>
<idno type="wicri:Area/PubMed/Curation">000168</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000168</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000008</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000008</idno>
<idno type="wicri:Area/Ncbi/Merge">002603</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Pharmacotherapeutics for the new coronavirus pneumonia].</title>
<author><name sortKey="Du, B" sort="Du, B" uniqKey="Du B" first="B" last="Du">B. Du</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Qiu, H B" sort="Qiu, H B" uniqKey="Qiu H" first="H B" last="Qiu">H B Qiu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009</wicri:regionArea>
<wicri:noRegion>Nanjing 210009</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhan, X" sort="Zhan, X" uniqKey="Zhan X" first="X" last="Zhan">X. Zhan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Y S" sort="Wang, Y S" uniqKey="Wang Y" first="Y S" last="Wang">Y S Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kang, H Y J" sort="Kang, H Y J" uniqKey="Kang H" first="H Y J" last="Kang">H Y J. Kang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, X Y" sort="Li, X Y" uniqKey="Li X" first="X Y" last="Li">X Y Li</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, F" sort="Wang, F" uniqKey="Wang F" first="F" last="Wang">F. Wang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sun, B" sort="Sun, B" uniqKey="Sun B" first="B" last="Sun">B. Sun</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tong, Z H" sort="Tong, Z H" uniqKey="Tong Z" first="Z H" last="Tong">Z H Tong</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</title>
<idno type="ISSN">1001-0939</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine (analogs & derivatives)</term>
<term>Adenosine (therapeutic use)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (therapeutic use)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Antiviral Agents</term>
<term>China</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Cytochrome P-450 CYP3A Inhibitors (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Lopinavir (therapeutic use)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Retrospective Studies</term>
<term>Ribonucleotides (therapeutic use)</term>
<term>Ritonavir (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adénosine (analogues et dérivés)</term>
<term>Adénosine (usage thérapeutique)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (usage thérapeutique)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Antiviraux</term>
<term>Association de médicaments</term>
<term>Chine</term>
<term>Humains</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Inhibiteurs du cytochrome P-450 CYP3A (usage thérapeutique)</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Ribonucléotides (usage thérapeutique)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine</term>
<term>Alanine</term>
<term>Anti-Bacterial Agents</term>
<term>Cytochrome P-450 CYP3A Inhibitors</term>
<term>Lopinavir</term>
<term>Ribonucleotides</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Adénosine</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adénosine</term>
<term>Alanine</term>
<term>Antibactériens</term>
<term>Inhibiteurs du cytochrome P-450 CYP3A</term>
<term>Lopinavir</term>
<term>Ribonucléotides</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Antiviraux</term>
<term>Association de médicaments</term>
<term>Chine</term>
<term>Humains</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The new coronavirus pneumonia (NCP), also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and interferon-α is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on Middle East respiratory syndrome (MERS), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg·kg(-1)·d(-1), 3~5 d) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32164081</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">1001-0939</ISSN>
<JournalIssue CitedMedium="Print"><Volume>43</Volume>
<Issue>3</Issue>
<PubDate><Year>2020</Year>
<Month>Mar</Month>
<Day>12</Day>
</PubDate>
</JournalIssue>
<Title>Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</Title>
<ISOAbbreviation>Zhonghua Jie He He Hu Xi Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Pharmacotherapeutics for the new coronavirus pneumonia].</ArticleTitle>
<Pagination><MedlinePgn>173-176</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.1001-0939.2020.03.005</ELocationID>
<Abstract><AbstractText>The new coronavirus pneumonia (NCP), also named as COVID-19 by WHO on Feb 11 2020, is now causing a severe public health emergency in China since. The number of diagnosed cases is more than 40,000 until the submission of this manuscript. Coronavirus has caused several epidemic situations world widely, but the present contagious disease caused by 2019 new coronavirus is unprecedentedly fulminating. The published cohorts of 2019 new coronavirus (n-Cov) are single-center studies, or retrospective studies. We here share the therapeutic experiences of NCP treatment with literature review. Combination of Ribavirin and interferon-α is recommended by the 5(th) edition National Health Commission's Regimen (Revised Edition) because of the effect on Middle East respiratory syndrome (MERS), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable. Systemic glucocorticosteroid is recommended as a short term use (1~2 mg·kg(-1)·d(-1), 3~5 d) by the 5(th) edition National Health Commission's Regimen (Revised Edition) yet RCTs are expected to confirm the effectiveness. Inappropriate application of antibiotics should be avoided, especially the combination of broad-spectrum antibiotics, for the NCP is not often complicated with bacterial infection.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Qiu</LastName>
<ForeName>H B</ForeName>
<Initials>HB</Initials>
<AffiliationInfo><Affiliation>Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhan</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Y S</ForeName>
<Initials>YS</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kang</LastName>
<ForeName>H Y J</ForeName>
<Initials>HYJ</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>X Y</ForeName>
<Initials>XY</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sun</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tong</LastName>
<ForeName>Z H</ForeName>
<Initials>ZH</Initials>
<AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>chi</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>2020YFC0841300</GrantID>
<Agency>Ministry of Science and Technology emergency response project to pneumonia pandemic of novel coronavirus infection</Agency>
<Country></Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Zhonghua Jie He He Hu Xi Za Zhi</MedlineTA>
<NlmUniqueID>8712226</NlmUniqueID>
<ISSNLinking>1001-0939</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065692">Cytochrome P-450 CYP3A Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012265">Ribonucleotides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>K72T3FS567</RegistryNumber>
<NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065692" MajorTopicYN="N">Cytochrome P-450 CYP3A Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012265" MajorTopicYN="N">Ribonucleotides</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherAbstract Type="Publisher" Language="chi"><AbstractText>新型冠状病毒肺炎(new coronavirus pneumonia,NCP)正在中国引起严重疫情,截至发稿之日,全国确诊人数已逾4万。冠状病毒已经在全世界范围内引起数次疫情,但此次疫情的来势之迅猛及传染性之强前所未有。我们对引起此次疫情的病原体——2019新型冠状病毒知之甚少,目前在国际上发表的临床研究文章或为单中心研究,或为回顾性分析。我们结合在新冠肺炎一线的救治体会及相关发表的研究成果,给大家分享新冠肺炎的治疗经验。抗病毒药物方面,目前仍无特效药物,利巴韦林和干扰素联合用药由于其治疗中东呼吸综合征(MERS)有效,仍被我国新冠肺炎诊疗方案推荐;洛匹那韦/利托那韦和瑞德西韦的疗效有待随机对照临床试验(randomized controlled trial,RCT)评价;糖皮质激素的短期应用(1~2 mg·kg(-1)·d(-1),3~5 d)被我国诊疗方案推荐,但仍需RCT进一步证实;本次新冠肺炎合并细菌感染较少,应当避免盲目使用抗菌药物,尤其避免联用广谱抗菌药物。.</AbstractText>
</OtherAbstract>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibiotics</Keyword>
<Keyword MajorTopicYN="N">Glucocorticosteroid</Keyword>
<Keyword MajorTopicYN="N">New coronavirus pneumonia</Keyword>
<Keyword MajorTopicYN="N">Pharmacotherapeutics</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>3</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32164081</ArticleId>
<ArticleId IdType="doi">10.3760/cma.j.issn.1001-0939.2020.03.005</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Du, B" sort="Du, B" uniqKey="Du B" first="B" last="Du">B. Du</name>
</noRegion>
<name sortKey="Kang, H Y J" sort="Kang, H Y J" uniqKey="Kang H" first="H Y J" last="Kang">H Y J. Kang</name>
<name sortKey="Li, X Y" sort="Li, X Y" uniqKey="Li X" first="X Y" last="Li">X Y Li</name>
<name sortKey="Qiu, H B" sort="Qiu, H B" uniqKey="Qiu H" first="H B" last="Qiu">H B Qiu</name>
<name sortKey="Sun, B" sort="Sun, B" uniqKey="Sun B" first="B" last="Sun">B. Sun</name>
<name sortKey="Tong, Z H" sort="Tong, Z H" uniqKey="Tong Z" first="Z H" last="Tong">Z H Tong</name>
<name sortKey="Wang, F" sort="Wang, F" uniqKey="Wang F" first="F" last="Wang">F. Wang</name>
<name sortKey="Wang, Y S" sort="Wang, Y S" uniqKey="Wang Y" first="Y S" last="Wang">Y S Wang</name>
<name sortKey="Zhan, X" sort="Zhan, X" uniqKey="Zhan X" first="X" last="Zhan">X. Zhan</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002603 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002603 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:32164081 |texte= [Pharmacotherapeutics for the new coronavirus pneumonia]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32164081" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |